Europe's Pharma Wake-Up: What It Costs Your DTC Brand

On July 16, 2026, Sandoz CEO Richard Saynor told Fortune that Europe spent decades optimizing its medicine supply chain for cost, and now it has no choice but to pay for resilience: roughly 70% of the drugs used across the continent are generics built almost entirely on active ingredients imported from China and India, and "reshoring all of Europe's supply chains is a great aspiration, but is also completely unrealistic." That's a pharma story, not a DTC one, but the same trade-off already showed up in the ecommerce supply chain you run: US import data shows the shift away from China already happened, and it matters because your landed cost is next in line. What to watch next: whether your own COGS stack is paying this same tax without you noticing.

I want to be upfront that the anchor here is a stretch. Sandoz and European pharma companies don't make consumer products, and nobody at Sandoz is thinking about your Shopify store. What they are dealing with, at a much bigger scale and with much less flexibility than you have, is the exact question every DTC operator has been living with since 2022: how much do you pay to not be one supplier away from a disaster. For the trade data behind the shift, see our nearshoring tracker for Mexico's rise, and for what a fractional CFO does with a resilience decision like this, read on.

What happened

Fortune published a commentary from Richard Saynor, CEO of Sandoz, one of the world's largest generic and biosimilar drug makers. His argument: roughly 70% of the medicines used across Europe are generics, and they account for only 10-20% of the total drug bill, because payers pushed prices down for decades. The catch is that almost none of the underlying active ingredients are made in Europe anymore. They come from China and India. Saynor's line: "Reshoring all of Europe's supply chains is a great aspiration, but is also completely unrealistic."

Sandoz isn't just talking. The company spent $711 million on capital expenditure in FY2025 (up $157 million year over year), and has committed more than $1.1 billion through 2029 to a biosimilar manufacturing hub in Slovenia, including a $440 million sterile-injectables plant at Brnik. On the policy side, the EU's Critical Medicines Act (covering roughly 300 active substances) reached a provisional political agreement between Parliament and Council on May 14, 2026, after being proposed in March 2025.

Europe's resilience reckoning (Sandoz, Fortune)	Figure
News event date	July 16, 2026 (Fortune commentary)
Share of European medicines that are generic	~70% (10-20% of total drug bill)
Sandoz FY2025 capital expenditure	$711M (+$157M YoY)
Sandoz Slovenia biosimilar hub, committed through 2029	$1.1B+
EU Critical Medicines Act	Provisional agreement, May 14, 2026

Source: Fortune commentary by Richard Saynor, Sandoz CEO (July 16, 2026); Sandoz FY2025 Financial Report and media release on the Slovenia investment.

The trade data already shows the shift: China down, Mexico up, Vietnam way up

Here's the part that isn't a European story. American ecommerce brands have been living a version of this exact trade-off for years, and the primary trade data shows it's booked, not projected.

China's share of US imports fell from 18.1% in 2019 to 8.8% in 2025, a collapse from $452.6 billion to $299.8 billion in absolute value, a 33.8% drop, even as total US imports grew nearly 36% over the same period. Mexico grew the other direction, from $355.8 billion to $533.3 billion (+49.9%), and overtook China as the single largest source of US imports somewhere between 2022 (when China was still ahead, $526.1B vs. $450.3B) and 2025. Vietnam roughly tripled, up 206.5%, and in knit apparel specifically (HS 61), Vietnam ($9.65B) has already passed China ($6.36B) as the bigger US source, a clean reversal from 2019 when China was still nearly double Vietnam's volume.

US import share by country	2019 value / share	2025 value / share	Change (value)
China	$452.6B / 18.1%	$299.8B / 8.8%	-33.8%
Mexico	$355.8B / 14.3%	$533.3B / 15.7%	+49.9%
Canada	$318.5B / 12.8%	$382.0B / 11.3%	+19.9%
Vietnam	$64.6B / 2.6%	$198.1B / 5.8%	+206.5%

If you sell furniture or home goods, the same pattern shows up hard: China-sourced furniture imports (HS 94) fell 52.2% since 2019. This isn't a single-category story, it's a broad reallocation of where the US buys physical goods, and it started well before the current tariff cycle accelerated it further in 2026.

Why this matters for your business

The shift away from China didn't happen because it got cheap to move. It happened alongside a steady rise in the cost of running any supply chain at all, which is the part that hits your margin whether or not you've personally changed a single supplier.

BLS Producer Price Index data (a measure of what businesses pay for a good or service before it reaches the shelf) shows warehousing and storage costs up 44.0% since 2019, and general freight trucking up 29.1% through the end of 2025, then accelerating sharply into 2026 (up 43.8% cumulative by June). Separately, the Import Price Index, flat for most of 2019-2025 (+12.6% cumulative), jumped 6.4% in just the first five months of 2026 as new tariffs landed. None of that is a resilience choice. It's the base cost of moving goods getting more expensive, full stop.

On top of that, retailers have rebuilt roughly half of the inventory they drew down during the pandemic. The inventories-to-sales ratio fell from 1.46 in 2019 to a 1.14 trough in 2021, then climbed back to 1.29 by 2025, about 47% of the gap recovered. That's a system-wide safety-stock rebuild happening quietly across retail, not a story about any one brand.

When we work through this with founders, the method is never "buy more of everything." It's ranking SKUs A, B, and C by volume and margin, and only the A's get the deep safety-stock investment. The C's often keep drop-shipping. That's the first-principles version of safety stock too: you start with zero, you build a buffer, and the buffer's whole job is to tell you when to reorder before you actually run out, not to insulate you from every possible disruption.

Here's a worked example that starts from the actual PPI moves above for the baseline inflation line, then layers in industry-benchmark premiums for the three deliberate levers. Take a $10M-revenue DTC brand with a 35% COGS line ($3.5M), a healthy-margin scenario (many $1-20M brands run 40-50% COGS, which would push every figure below higher), and assume roughly 10% of COGS is logistics-related spend:

Line	Added annual cost
Freight + warehousing inflation already in your P&L (no strategy change, ~10% of COGS is logistics-related)	$120K-$140K
Dual sourcing on 25% of SKUs (+5-10% procurement premium)	$44K-$88K
Nearshoring on 20% of SKUs (+8-25% per-unit premium)	$56K-$175K
Extra safety stock, ~$300K added inventory (+10-20% carrying cost)	$30K-$60K
All-in total, including the baseline inflation line above	~$250K-$460K/year (2.5-4.6% of revenue)

That range is wide on purpose. Which end you land on depends entirely on how much of your product line actually needs the insurance, which is the next question.

The decision matrix: which resilience lever is worth it at your revenue scale

Industry research (BCG, Capgemini, Inverto, and inventory-management practitioner guides) converges on rough ranges for each lever, treated here as directional benchmarks, not audited figures.

Lever	Typical added cost	What it buys
Dual sourcing	+5-10% procurement cost	Redundancy if one supplier fails
Safety stock	+10-20% inventory carrying cost	Buffer against lead-time variability
Nearshoring	+8-25% per-unit cost	Shorter lead times, lower tariff/freight exposure

Source: synthesis of BCG, Capgemini, and inventory-management industry benchmarks (secondary sources; treat ranges as directional, not audited figures).

Under $5M in revenue. Skip the deliberate spend for now. Do the free version first: figure out which SKUs have exactly one supplier and no substitute. That list is your real exposure, and it's usually a fraction of your catalog.

$5M-$20M in revenue. Dual sourcing on your A-tier SKUs (the ones ranked highest by revenue and margin) is usually worth the 5-10% premium. Safety stock follows the same rule, buffer the A's, keep the C's lean or drop-shipped. Nearshoring is worth pricing out but rarely worth committing to yet unless one supplier accounts for a dangerous share of a single category.

$20M-$150M in revenue. This is where nearshoring starts to pencil out on a real landed-cost comparison, because you have the volume to negotiate minimum order quantities with a second supplier. It's also where the multi-warehouse question matters: how many fulfillment nodes you carry inventory in changes your cash position as much as how much inventory you hold. One thing every founder we talk to at this stage eventually says the same version of: nobody wants to sit on cash that does nothing, but every brand that carried extra cash going into 2022 was glad they had it by 2023. Resilience spend is the inventory version of that same insurance logic.

What to do this week

Three moves, in order of how cheap they are to make.

Audit your single-source SKUs. List every product where one supplier failing would actually break a quarter. This is the free step and most brands haven't done it in over a year.

Quantify your current safety-stock carrying cost. Multiply your average on-hand inventory value by roughly 20-30% to see what you're already paying to hold buffer stock. Compare that number to what an actual stockout on your top SKU would cost you in lost revenue.

Get a real landed-cost quote from a Mexico or Vietnam alternate supplier before you commit to anything. The 8-25% nearshoring premium ranges are directional. Your actual number, including freight, duty, and MOQ, is knowable in a week and is the only number that should drive the decision.

Sources and methodology

US Census Bureau international trade timeseries is the primary source for every import-share figure above. Values are US imports for consumption by partner country, nominal USD, not inflation-adjusted, pulled for total, China, Mexico, Canada, and Vietnam across 2019, 2022, and 2025, plus HS 61 (knit apparel) and HS 94 (furniture) at the category level.

BLS Producer Price Index tracks warehousing and freight cost separately from tariffs. Series PCU493---493--- (warehousing and storage) and PCU484---484--- (general freight trucking), base December 2003=100, monthly through June 2026. The 2026 reading is preliminary and subject to revision.

FRED provided the inventory rebuild and 2026 import-price acceleration data. The Retailers: Inventories to Sales Ratio (RETAILIRSA) and the Import Price Index: All Commodities (IR) series are both seasonally unadjusted or adjusted as noted; the Import Price Index should be read as percent change over comparable periods, not a level.

Public company filings confirm freight, not tariffs, is the more consistent cost driver right now. Stitch Fix's Q3 FY2026 10-Q states tariffs have not materially impacted cost of goods sold, but rising transportation cost has. Columbia Sportswear's FY2025 10-K names "Rapidly Evolving U.S. Global Trade Policy" as a standalone risk factor.

The resilience-premium ranges (dual sourcing, safety stock, nearshoring) are industry benchmarks, not audited company data. They come from named research firms (BCG's "Balancing Cost and Resilience," Capgemini's supply-chain resilience research, the Inverto nearshoring survey of roughly 95 manufacturers) plus consensus practitioner guidance on inventory carrying cost. Treat them as directional ranges, the way this piece uses them, not as a formula that applies to your specific product.

The Sandoz and EU policy figures are drawn from primary company and institutional disclosure. Sandoz's FY2025 Financial Report and its Slovenia investment media release are the source for the $711M capex and $1.1B+ commitment figures. The EU Critical Medicines Act dates come from European Commission and European Parliament records.

Sources: Fortune, Sandoz media release, US Census Bureau, BLS PPI, FRED, BCG. For the tariff exposure by category behind this shift, see our DTC tariff exposure index, and for what it's doing to fulfillment pricing, our 3PL cost index.

Frequently asked questions

what does supply chain resilience actually cost as a percent of cogs?

It depends on which lever you pull and how much of your product line you apply it to. Industry ranges put dual sourcing at +5-10% procurement cost, safety stock at +10-20% additional carrying cost, and nearshoring at +8-25% per unit, but those percentages apply to the share of COGS you choose to protect, not your entire line. For a $10M-revenue brand applying all three to 20-25% of SKUs, the all-in cost, including the freight and warehousing inflation already baked into your numbers, runs roughly $250K-$460K a year.

is nearshoring to mexico actually cheaper than sourcing from china now?

Not on a pure unit-cost basis in most cases. Nearshoring typically runs 8-25% more per unit than offshore sourcing. The case for it is shorter lead times, lower freight and tariff exposure, and fewer stockouts, not a lower sticker price. It becomes worth it when your disruption risk (a blown Q4, a tariff spike, a single-factory failure) costs more than the premium, which is a real calculation, not a vibe.

how much extra safety stock should a dtc brand carry in 2026?

Only as much as your A-tier SKUs need, not a blanket increase across your catalog. Safety stock is the buffer inventory you hold so that when you dip into it, you know to place your next order before you actually stock out. Rank products by volume and margin, then size the buffer around your best sellers and your single-source SKUs. Carrying cost typically runs 20-30% of inventory value a year, so buffering your whole catalog is usually the wrong call.

has mexico really overtaken china as a bigger source of us imports?

Yes, and it already happened, not a forecast. US Census data shows Mexico's import value grew from $355.8B in 2019 to $533.3B in 2025, while China fell from $452.6B to $299.8B over the same period. China was still ahead of Mexico as recently as 2022 ($526.1B vs. $450.3B), so the crossover is a genuinely recent shift.

is dual sourcing worth it for a brand under $10m in revenue?

Usually only for your single-source, high-revenue SKUs, not your whole catalog. Under $10M, margin for error is thin and a 5-10% procurement premium across many products can outweigh the benefit. The move that pays off first is free: identify which SKUs have exactly one supplier and no substitute, because that's your actual exposure, not your total product count.

why is europe's medicine shortage relevant to a us ecommerce brand?

Because it's the same trade-off at a bigger scale. Europe optimized its generic-drug supply chain so hard for cost that it now depends almost entirely on China and India for active ingredients, and its CEO says full reshoring is unrealistic. US ecommerce brands made a smaller, faster version of that same bet on China sourcing after 2015, and the import data shows the same unwind already underway: China's import share nearly halved since 2019.

how do tariffs actually hit my gross margin vs my freight costs?

Differently, and it matters which one is driving your number. Tariffs hit landed cost directly, dollar for dollar, on the goods subject to them. Freight and warehousing inflation (up 29-44% since 2019 per BLS) hits every shipment regardless of country of origin. Public filings back this up: Stitch Fix's most recent 10-Q says tariffs haven't materially moved its cost of goods sold, but rising transportation cost has. Check which line is actually moving before you assume tariffs are the problem.